-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 16, 2022, Bristol-Myers Squibb Company (BMS) announced positive results from a Phase 3 clinical trial of mavacamten
oHCM is a chronic progressive disease that thickens the walls of the heart, making it difficult for the heart to expand properly and fill with blood, leading to a variety of debilitating symptoms and cardiac dysfunction, and is a common cause of cardiac arrest in young adults
Mavacamten is an innovative oral selective cardiac myosin allosteric modulator that targets the underlying pathophysiology of oHCM and is expected to reduce symptoms of cardiac hypercontractility in patients
The randomized, double-blind, placebo-controlled, multicenter Phase 3 clinical trial was conducted in patients with symptomatic oHCM who met guideline criteria for the treatment of ventricular septal reduction and who were recommended by their physicians for invasive surgery
The primary endpoint was a composite of the number of patients who decided to undergo septal-reducing therapy at or before week 16 and the number of patients who remained eligible for septal-reducing therapy at week 16
References:
[1] Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy.
[2] A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy (VALOR-HCM).
(Original abridged)
